Discover
LBRX
LB Pharmaceuticals Inc Common Stock
44.80
1 x 44.49
1 x 44.86
bid
ask
-
1.05
2.29%
12:36 PM
timesize
| Ytd | 101.26% | |
| 1y | 158.96% |
43.61
day range
46.27
13.36
52 week range
49.14
| Open | 45.93 | Prev Close | 45.85 | Low | 43.61 | High | 46.27 | Mkt Cap | 1.29B |
| Vol | 58.76K | Avg Vol | 304.74K | EPS | -1.73 | P/E | -25.91 | Forward P/E | -11.47 |
| Beta | N/A | Short Ratio | 11.99 | Inst. Own | 109.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 33.46 | 200-d Avg | 25.68 | 1yr Est | 45.88 |
| Income Statement | |||
| Operating Expenses | 22.10M | ||
| Research and Development Expense | 14.65M | ||
| Selling, General and Administrative Expense | 7.46M | ||
| Operating Income | -22.10M | ||
| Net Income | -19.05M | ||
| Net Income Common Stock | -19.05M | ||
| Net Income Common Stock (USD) | -19.05M | ||
| Consolidated Income | -19.05M | ||
| Earnings per Basic Share | -0.67 | ||
| Earnings per Basic Share (USD) | -0.67 | ||
| Earnings per Diluted Share | -0.67 | ||
| Earning Before Interest & Taxes (EBIT) | -19.05M | ||
| Earning Before Interest & Taxes (USD) | -19.05M | ||
| Weighted Average Shares | 28.24M | ||
| Weighted Average Shares Diluted | 28.24M | ||
| Balance Sheet | |||
| Cash and Equivalents | 321.45M | ||
| Cash and Equivalents (USD) | 321.45M | ||
| Investments | 44.96M | ||
| Investments Current | 44.96M | ||
| Current Assets | 389.07M | ||
| Property, Plant & Equipment Net | 3.63M | ||
| Total Assets | 393.48M | ||
| Debt Current | 730.00K | ||
| Total Debt | 3.47M | ||
| Current Liabilities | 10.91M | ||
| Debt Non-Current | 2.74M | ||
| Total Liabilities | 14.79M | ||
| Accumulated Retained Earnings (Deficit) | -148.58M | ||
| Accumulated Other Comprehensive Income | 208.00K | ||
| Shareholders Equity | 378.69M | ||
| Shareholders Equity (USD) | 378.69M | ||
| Assets Non-Current | 4.41M | ||
| Total Debt (USD) | 3.47M | ||
| Liabilities Non-Current | 3.88M | ||
| Trade and Non-Trade Payables | 7.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 132.00K | ||
| Net Cash Flow from Financing | 93.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 70.51M | ||
| Capital Expenditure | -32.00K | ||
| Issuance (Purchase) of Equity Shares | 93.83M | ||
| Net Cash Flow from Investing | -32.00K | ||
| Net Cash Flow from Operations | -23.29M | ||
| Share Based Compensation | 2.57M | ||